ULiège, CHU - FNRS
" We aim to compare various diagnostic tools (swabs, saliva, serology, antigen detection) in order to define the best one depending on the clinical presentation and the duration of the disease. "
Funding: Fonds Léon Fredericq FNRS
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
ULiège, CHU - FNRS
" We aim to define the clinical characteristics associated with the production and the level of neutralizing antibodies (NAbs) in COVID19 recovered patients. In particular, we will investigate whether the development of a strong and persistent humoral immune response takes place in severely affected, individuals with mild symptoms or asymptomatic individuals. We will also study the study the persistence of NAbs overtime. "
Funding: Fonds Léon Frédéricq FNRS
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
ULiège, CHU
" La recherche de biomarqueurs fiables, sensibles et peu invasifs est un enjeu de premier ordre pour la médecine moderne. En effet, ces biomarqueurs ont le potentiel de transformer la prise en charge médicale en améliorant le dépistage et le diagnostic, mais aussi en permettant de mieux appréhender la physiopathologie d'une pathologie ou sa réponse à un traitement donné. Fort de nos travaux précédents, nous proposons de réaliser une étude prospective sur une population adulte souffrant d'un SDRA modéré à sévère post SARS-COV2 afin de caractériser une signature exosomique plasmatique propre à cette population. "
Funding: FLF FIRS CHU de Liège
Publication References: hankar-Hari, M., Fan, E. & Ferguson, N. D. Acute respiratory distress syndrome (ARDS) phenotyping. Intensive Care Med. (2018). 45;(4): 516-519. Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. N Engl J Med. 2017;377(6):562–72. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle...
CHU Liege/ULiège
" La nouvelle pandémie COVID-19 modifie la prise en charge des patients oncologiques. Le premier objectif de notre projet est d'étudier la sécurité de la poursuite des traitements systémiques anti-tumoraux dans le contexte actuel de pandémie. Le deuxième objectif est de comprendre les inquiétudes et les ressentis de nos patients par rapport au risque d'attraper l'infection et leurs conséquences. Le troisième objectif est d'évaluer le taux d'infection et de séroconversion asymptomatique chez nos patients en comparaison à la population globale. Le quatrième objectif est de mieux comprendre les raisons de détresse du personnel soignant en oncologie afin de mieux organiser des mesures de soutien psychologique. "
Funding: Fondation Leon Frederic Fonds propres Oncologie Médicale
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
ULB - FNRS
" - I use my expertise in clinical research to set up and coordinate the reception/labeling and encoding station at the COVID diagnostic platform at ULB - As new president of the BSRM, I coordinate the writing and diffusion o recommendations for the reproductive centers in Belgium regarding COVID-19 pandemic "
Contact: https://actus.ulb.be/fr/actus/recherche/tests-de-diagnostic-covid-19-plus-de-250-chercheurs-mobilises BSRM website (https://bsrm.be)
Comment: My role as president of the BSRM to manage the COVID-19 crisis and my participation as coordinator at the COVID diagnostic platform (ULB) are completely independent.
ULB Hôpital Erasme - FNRS
" Genetic modifiers of the clinical response to infection by SARS-CoV-2 (COVID-19). The project is part of a global effort of the human genetics community to generate, share and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity and outcomes in all patients, as well as identify genetic errors that make some younger patients especially vulnerable to the virus. DNA samples and clinical data for COVID-19 patients are collected for GWAS analysis, whole exome, and/or whole genome sequencing. Such discoveries could help to generate hypotheses for drug repurposing, identify individuals at unusually high or low risk, and contribute to global knowledge of the biology of SARS-CoV-2 infection and disease. "
Funding: -ULB -Fondation Erasme
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it.
ULB, Department of Pathology, Erasme hospital and DIAPath-CMMI - Royal Academy of Medicine of Belgium
" A first objective of this project is to establish an accurate topography of the SARS-CoV-2 virus in the organs and various cells of patients who died in COVID-19 units, in order to contribute to a better understanding of the pathogenesis of COVID-19. A second objective is to provide a routine diagnostic test for the detection of SARS-CoV-2 in routine samples in pathological anatomy. "
Funding: Fonds Y Boël (Brussels, Belgium), Fonds Erasme pour la Recherche Médicale (Brussels, Belgium), and "Appel à projet Spécial COVID-19 - ULB" (Brussels, Belgium). The CMMI is supported by the European Regional Development Fund and the Walloon Region of Belgium (Wallonia-biomed; grant no. 411132-957270; project "CMMI-ULB").
Contact: Prof. I. Salmon, Department of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070 Brussels, Belgium.
ULiège and CHU de Liège
" BACKGROUND The SARS-CoV2 or COVID-19 infection is unique in terms of its speed of spread, the importance of structural medical reorganization, the length of resuscitation stays sometimes required, the diversity of the affected population, especially young or fragile subjects, and the impacts on physical and mental health generated by this pandemic and the prolonged confinement of populations. Muscle damage related to immobility, inflammation, corticosteroids, hypoxemia associated with pulmonary and cardiac damage, and metabolic damage (undernutrition), all sometimes linked to the infection, suggests weak or major functional repercussions, already described in SARS patients. Thus, the patients most affected by COVID-19 require acute hospital management and sometimes complex rehabilitation management. Retrospective studies of the functional capacities of patients with SARS of viral origin show the persistence of functional impairment at a distance from the...
UMONS/Epicura
" We set up a pilot study including positive COVID-19 patients hospitalized in intensive care with acute renal disorders. The primary intention here is to assess the serum and urine metabonomic profiles of patients with renal disorders following SARS COV-2 infection at the time of their hospitalization in order to identify metabolic indicators of the acute renal injury. "
Funding: internal funding and CUR/FNRS project submitted
Publication References:
1. Lindon JC, Nicholson JK, Holmes E, Antti H, Bollard ME, Keun H, Beckonert O, Ebbels TM, Reily MD, Robertson D, Stevens GJ, Luke P, Breau AP, Cantor GH, Bible RH, Niederhauser U, Senn H, Schlotterbeck G, Sidelmann UG, Laursen SM, Tymiak A, Car BD, Lehman-McKeeman L, Colet JM, Loukaci A, Thomas C. Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol Appl Pharmacol. 187(3):137-46 (2003)
2. Colet Jean-Marie, ""Metabonomics in the Preclinical and...
Read more: Jean-marie Colet, Pr. - Anne-Emilie Declèves, Pr. - Frédéric Debelle, Dr
UCLouvain - FNRS
" In collaboration with the University of Rwanda, pro-inflammatory and anti-inflammatory cytokines will be measured in the plasma of COVID-19 patients and their level will be correlated with the severity of the disease. "
Funding: ARES-CCD
Publication References: Ndoricyimpaye EL, Tuyishimire J, Vanwambeke S, Mutesa L, Nyandwi E, Rujeni N, Coutelier J-P. L'épidémie de SARS-CoV-2 en Afrique sub-Saharienne, questions, craintes et espoirs. Louvain Médical, submitted.
Contact: Prof. J.-P. Coutelier de Duve Institute Universite Catholique de Louvain SSS/DDUV - ICP Av. Hippocrate 75, bte B1.74.05 1200 Woluwe-Saint-Lambert, Belgique tel 32 2 764 7437 fax 32 2 764 7430 e-mail This email address is being protected from spambots. You need JavaScript enabled to view it.
ULB, Faculty of Medicine, and Erasme Hospital
Suivi longitudinal de biomarqueurs sériques et urinaires de l'atteinte rénale aiguë associée au COVID-19 : impacts diagnostique et pronostique. " L'objectif principal de cette étude est de caractériser l'atteinte rénale aiguë par le virus SARS-COV2 chez des patients hospitalisés présentant une maladie COVID-19 à l'aide de biomarqueurs sériques et urinaires précoces et spécifiques à certains segments du néphron. L'objectif secondaire est d'établir une corrélation entre l'évolution de ces marqueurs observée durant la phase aiguë de l'insuffisance rénale et le passage éventuel à un stade chronique. "
Funding: Crédit Urgent de Recherche (CUR) sollicité auprès du FNRS
Publication References: BUNEL V, SOUARD F, ANTOINE M-H, STEVIGNY C, NORTIER JL. Nephrotoxicity of Natural Products: Aristolochic Acid and Fungal Toxins. In McQueen C.A., Comprehensive Toxicology, Third Edition. Vol 14, Oxford Elsevier Ltd (2018), pp 340-379. BUNEL V, TOURNAY Y...
Erasme Hopital
" Nutritional assessment and support for optimal rehabilitation following COVID 19 critical illness "
Funding: NA
Contact: NA
CHU-Liège
" The University Hospital of Liège (CHULiège) has developed a diagnostic capability to detect the SARS-CoV-2 by RT-PCR in response to the need for more capacity testing in Belgium from March 2020. Indeed, from February 2020, clinical COVID-19 cases were already detected in Belgium thanks to the Reference laboratory for respiratory viruses in KULeuven (Reflab). However, it appeared rapidly evident that the capacity of the Reflab could not be further enhanced. Therefore Belgian university and non-university hospital laboratories started to develop RT-PCR assays which sensitivity were first validated by the Reflab. CHULiège developed an in house SARS-CoV-2 RT-PCR assay following an adapted version of the Charité Hospital (1) protocol with the aid of the Antwerp University Hospital Microbiology lab and the Reflab. We have chosen to include two targets: the E and RNA-dependent RNA polymerase (RdRP) genes. From the 6th March, we were able to run the test and since this date we run...
CUB-Erasme
" "Background: There are no currently approved therapeutics for COVID-19 disease. This disease causes significant morbidity and mortality. Main Objectives: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19 patients. The primary endpoint is subject clinical status (on a 7-point ordinal scale) on Day 15. The secondary objectives are to evaluate clinical, and virological efficacy, and safety of different investigational therapeutics as compared to the control arm. Study design: This is a prospective, worldwide, adaptive, randomized, controlled, open study comparing 4 different treatments for COVID-19. The protocol is based on the WHO Master protocol of the Solidarity trial. The DisCoVeRy protocol previews more data collection and lower dosage regimens of Hydroxychloroquine than in the SOLIDARITY trial. Randomization is performed by...
CUB-Erasme
" "a. Background Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a new coronavirus SARS CoV-2, responsible for the current pandemic, causing a lot of morbidity and mortality. Most people with COVID-19 develop mild respiratory illness (stage I). However, in a sub-group of patients (+/- 15%) there are increasing respiratory symptoms and persistent fever (stage II). Patients may develop acute lung injury (hypoxia, and bilateral opacities on chest computed tomography (CT-scan)), requiring hospitalisation. A further 5% of patients develop stage III disease, requiring admission to the intensive care unit (ICU) due to acute respiratory distress syndrome (ARDS), sepsis and septic shock, and multi-organ failure. As patients progress from stage I to stage III, there are increasing signs of systemic hyper-inflammatory response, reflected by high levels of cytokines, C-reactive protein (CRP), ferritin, and lymphopenia. Different viral, bacterial, and...
